Flt-4 Monoclonal Antibody

This gene encodes a tyrosine kinase receptor for vascular endothelial growth factors C and D. The protein is thought to be involved in lymphangiogenesis and maintenance of the lymphatic endothelium. Mutations in this gene cause hereditary lymphedema type IA.

The FLT-4 Monoclonal Antibody is a cutting-edge pharmaceutical product that has been meticulously developed to target and inhibit the FLT-4 receptor, a key player in angiogenesis and lymphangiogenesis processes. This antibody, derived from a single clone, exhibits exceptional specificity and affinity towards FLT-4, making it an invaluable tool for researchers and clinicians alike.

With its advanced technology and rigorous quality control measures, the FLT-4 Monoclonal Antibody ensures consistent and reliable results in various applications, including immunohistochemistry, flow cytometry, and Western blotting. Its exceptional performance in these techniques enables accurate detection and quantification of FLT-4 expression levels, facilitating a deeper understanding of its role in physiological and pathological conditions.

Furthermore, the FLT-4 Monoclonal Antibody demonstrates remarkable stability and durability, ensuring long-term storage without compromising its efficacy. This feature, coupled with its ease of use and compatibility with multiple experimental protocols, makes it an ideal choice for laboratories and research institutions seeking a dependable and versatile tool for FLT-4-related investigations.

In summary, the FLT-4 Monoclonal Antibody represents a breakthrough in the field of molecular biology, offering researchers and clinicians a highly specific and reliable means to study and target the FLT-4 receptor. Its exceptional performance, stability, and compatibility make it an indispensable asset in the pursuit of understanding and combating angiogenesis and lymphangiogenesis-related disorders.